An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when

Jo Caers, Laurent Garderet, K. Martin Kortüm, Michael E. O'Dwyer, Niels W.C.J. van de Donk, Mascha Binder, Sandra Maria Dold, Francesca Gay, Jill Corre, Yves Beguin, Heinz Ludwig, Alessandra Larocca, Christoph Driessen, Meletios A. Dimopoulos, Mario Boccadoro, Martin Gramatzki, Sonja Zweegman, Hermann Einsele, Michele Cavo, Hartmut Goldschmidt, Pieter Sonneveld, Michel Delforge, Holger W. Auner, Evangelos Terpos, and Monika Engelhardt

Disclosures: J Caers reported honoraria/research funding and participation in advisory boards from Amgen, Janssen and Celgene M O Dwyer reported honoraria/research funding and participation in advisory boards from Janssen, Abbvie, Celgene, Glycomimetics and Carrick Therapeutics Meletios-Athanasios Dimopoulos reported honoraria/research funding and participation in advisory boards from Celgene, Janssen, Takeda, Amgen, Abbvie A Larocca reported honoraria/research funding and participation in advisory boards from Celgene, Janssen, Bristol-Myers Squibb, Amgen and Adaptive Biotechnology H Goldschmidt reported honoraria/research funding and participation in advisory boards from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Mundipharma, Takeda, Sanofi, Novartis, Chugai, BMS, ArtTempi and Adaptive Biotechnology E Terpos reported honoraria/research funding and participation in advisory boards from Amgen, Bristol-Myers Squibb, Celgene/Genesis, Janssen and Takeda. F Gay reported honoraria/research funding and participation in advisory boards from Amgen, Celgene, Roche, Takeda and Janssen, M Binder reported honoraria/research funding and participation in advisory boards from Celgene, Takeda, Roche, Gilead, Bristol-Myers Squibb, Sanofi, Amgen, Chugai and Hexal Biosimilars. H Einsele reported honoraria/research funding and participation in advisory boards from Celgene, Janssen, Novartis, Bristol-Myers Squibb and Amgen N van de DONK reported honoraria/research funding and participation in advisory boards from Janssen Pharmaceuticals, Celgene, Bristol-Myers Squibb, AMGEN, Servier, Novartis and Bayer HW Auner reported honoraria/research funding and participation in advisory boards from Hallemavanloon, Novartis, PharMar, Takeda, Karyopharm and Amgen

Contributions: JC, LG, SMD, MB, MKM, ET and ME drafted the first version. All other authors commented on and corrected further on the manuscript.